The emergence of biosimilars leads to a shocking FDA panel decision that I guarantee you've never seen before.
AbbVie's guidance suggests that the threat from biosimilars isn't too scary... at least for now.
Motley Fool contributors target three biotechs that could energize your portfolio in 2016.
AbbVie's CEO discusses its three most important products, three key pipeline drugs, and what catalysts shareholders should keep their eyes on in 2016.
It was another rough week for healthcare ETFs, but this fund held up better than the rest.
Guidance for $37 billion in sales in 2020 suggests that AbbVie can sidestep threats of a generic Humira.
Thinking about investing in CVS Health because of its dividend? Here are three other healthcare stocks you might want to consider instead.
Two therapeutic franchises will prove key in determining whether or not Johnson & Johnson enjoys its best year ever in 2016.
An analyst upgrade sent share of the drugmaker higher today.
The FDA's approval of new cardiovascular and oncology disease drugs are among the most notable of the year.